Opus Genetics, Inc. (IRD)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 0 | 1 | 40 | 19 | 11 | 14 | 10 | 12 |
| Operating profit | $m | -39 | -51 | ||||||
| Net profit | $m | -25 | -57 | 18 | -10 | -58 | -50 | -108 | - |
| EPS reported | $ | -0.80 | -1.27 | ||||||
| Operating cashflow per share | $ | -0.06 | -0.43 | ||||||
| Capex per share | $ | 0.00 | 0.00 | ||||||
| FCF per share | $ | -0.06 | -0.43 | ||||||
| Free cash flow | $m | -35 | -41 | ||||||
| Net debt | $m | -45 | -54 | ||||||
| Book value equity | $m | 15 | -13 | ||||||
| Book value per share | $ | 0.02 | -0.12 | ||||||
| Number of shares | m | 622.22 | 111.38 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 81.49 | -96.31 | ||||||
| P/S LTM | x | 88.10 | 126.89 | ||||||
| P/FCF LTM | x | -35.48 | -30.75 | ||||||
| EV/EBITDA LTM | x | -25.08 | -11.49 | ||||||
| EV/Sales LTM | x | 84.92 | 24.78 | ||||||
| Earnings Yield LTM | % | -3.97% | -31.22% | ||||||
| FCF Yield | % | -2.82% | -3.25% | ||||||
| Quality | |||||||||
| ROE | % | -323.11% | +1147.6% | ||||||
| ROIC | % | -90.90% | -59.29% | ||||||
| Operating margin | % | -2.72% | -5.13% | ||||||
| Gross margin | % | +100.00% | +99.87% | ||||||
| FCF/Sales | % | -248.33% | -412.61% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | +29.15% | -10.33% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | - | -1.16 | ||||||
| Net Debt/EBITDA | x | 0.94 | 0.51 | ||||||
| EBIT/Net interest | x | -26.33 | -19.11 | ||||||
| Net debt/market cap | % | 0.00% | +11.72% | ||||||
| Net debt/Equity | x | -2.94 | 4.15 | ||||||
| Gross debt/equity | x | 0.00 | -2.69 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Opus Genetics, Inc. is a clinical-stage biopharmaceutical company focused on ophthalmology. The company is dedicated to discovering and commercializing innovative therapies to address significant unmet medical needs in patients suffering from refractive and retinal eye disorders. Its portfolio includes Phentolamine Ophthalmic Solution, currently used to reverse pharmacologically induced mydriasis (pupil dilation). This solution is also advancing through Phase III clinical trials for the treatment of presbyopia and impaired vision in dim light or at night. A leading candidate in its retinal pipeline is APX3330, a small-molecule inhibitor targeting the reduction oxidation effector factor-1 protein. APX3330 has successfully completed Phase II clinical trials for diabetic retinopathy. Furthermore, Opus Genetics is developing APX2009 and APX2014, two preclinical product candidates also aimed at various retinal indications. Originally founded in 2018 as Ocuphire Pharma, Inc., the company maintains its headquarters in Farmington Hills, Michigan.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Opus Genetics, Inc. is a clinical-stage biopharmaceutical company focused on ophthalmology. The company is dedicated to discovering and commercializing innovative therapies to address significant unmet medical needs in patients suffering from refractive and retinal eye disorders. Its portfolio includes Phentolamine Ophthalmic Solution, currently used to reverse pharmacologically induced mydriasis (pupil dilation). This solution is also advancing through Phase III clinical trials for the treatment of presbyopia and impaired vision in dim light or at night. A leading candidate in its retinal pipeline is APX3330, a small-molecule inhibitor targeting the reduction oxidation effector factor-1 protein. APX3330 has successfully completed Phase II clinical trials for diabetic retinopathy. Furthermore, Opus Genetics is developing APX2009 and APX2014, two preclinical product candidates also aimed at various retinal indications. Originally founded in 2018 as Ocuphire Pharma, Inc., the company maintains its headquarters in Farmington Hills, Michigan.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free